A clinical study of non-bioartificial liver DPMAES support system in hepatitis B-related acute-on-chronic liver failure

Xianwen Cheng,Yanrong Zhan,YaoShun Liu,Xia Zeng,Zhendong Wang,Feng Wang,Ya Mao,Song Na

DOI: https://doi.org/10.1038/s41598-024-52206-0

IF: 4.6

2024-01-22

Scientific Reports

Abstract:This study aims to observe the clinical efficacy of the dual plasma molecular adsorption exchange system (DPMAES) in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF), with a focus on its regulatory effect on cytokine storm. A total of 60 HBV-ACLF patients were enrolled in this study. The observation group, comprising 30 patients, received DPMAES treatment, while the control group underwent PE treatment. We compared the efficacy changes between the two groups post-treatment. A total of 55 HBV-ACLF patients who completed the study were analyzed, Patients treated with DPMAES showed significant improvements in clinical outcomes. After DPMAES treatment, HBV-ACLF patients exhibited notably 90 day survival rate increased by 18% compared to those in the PE group. Moreover, total bilirubin levels decreased markedly, albumin and platelet levels increased compared to the PE group. After DPMAES treatment, the patient showed a significant decrease in inflammatory cytokine IL-6 (t = 5.046, P < 0.001) and a significant decrease in procalcitonin (t = 4.66, P < 0.001). DPMAES was more effective than PE in rapidly reducing TBiL, improving coagulation function and mitigating cytokine storm. It maintained platelet stability more effectively while minimizing albumin consumption to a greater extent, significantly improved 90-day survival.

multidisciplinary sciences

What problem does this paper attempt to address?

This paper aims to study the clinical efficacy of the Double Plasma Molecular Adsorption Exchange System (DPMAES) in patients with Hepatitis B Virus-related Acute-on-Chronic Liver Failure (HBV-ACLF), with a particular focus on its regulatory effect on cytokine storms.

Specifically, the study compares 60 HBV-ACLF patients who were randomly divided into two groups: the observation group received DPMAES treatment, while the control group received Plasma Exchange (PE) treatment. The main findings of the study include:

1. **Survival Rate**:
- During the 90-day follow-up, the survival rate in the DPMAES treatment group significantly increased, by 18% more than the PE group.

2. **Biochemical Indicators**:
- After DPMAES treatment, patients' total bilirubin (TBil) levels significantly decreased, and albumin (ALB) levels significantly increased, while there were no significant changes in the PE group.
- Patients' coagulation function improved, but there was no significant difference between the two groups.
- Platelet count significantly recovered in the DPMAES group, but there was no significant change in the control group.

3. **Inflammatory Markers**:
- After treatment, the levels of inflammatory factors IL-6 and procalcitonin (PCT) in the DPMAES group significantly decreased, more so than in the PE group.

4. **HBV-DNA Levels**:
- After treatment, the HBV-DNA levels in the DPMAES group were significantly lower than those in the PE group, with the difference being more pronounced at 90 days.

In summary, DPMAES not only effectively improves the survival rate of patients but also significantly reduces inflammatory responses and viral load, thereby providing better treatment outcomes for HBV-ACLF patients.